newsfilter
← Latest News
Business Wire·

EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

Milestone follows prestigious oral plenary presentation of EXPAND data at SMFM Annual Meeting Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that